Shuang Jiang1, Meng-Meng Zhou2, Rong Xia1, Jing-Hui Bai3, Li-Hui Yan4. 1. Department of Internal Medicine (Psychologic Clinic), Cancer Hospital of China Medical University, Shenyang, 110042, China. 2. Department of Psychology Clinic, Shengjing Hospital of China Medical University, Shenyang, 110022, China. 3. Department of Internal Medicine (VIP Ward), Cancer Hospital of China Medical University, Shenyang, 110042, China. 4. Department of Internal Medicine (Pain Clinic), Cancer Hospital of China Medical University, No. 44 Xiaoheyan Road, Dadong District, Shenyang, 110042, China. yanlh2005@sina.com.
Abstract
BACKGROUND: Phantom limb pain (PLP) is a prevalent problem for children after amputation because of the chemotherapy treatment. Gabapentin is a potential option to manage PLP after amputation in pediatric oncology. However, no systematic review specifically investigated this topic. Thus, this study aims to appraise the efficacy and safety of gabapentin for post-amputation PLP in pediatric oncology. METHODS: Electronic databases (Cochrane Library, MEDLINE, EMBASE, Web of Science, CINAHL, PsychINFO, Scopus, WANGFANG, and Chinese Biomedical Literature Database) will be systematically searched from the beginning to the present without limitations to publication status and language. Primary outcome is pain intensity. Secondary outcomes are analgesic drug consumption, sleep quality, depression, anxiety, health-related quality of life, and adverse events. The treatment effect of all dichotomous outcome data will be estimated as risk ratio and 95% confidence intervals (CIs) and that of continuous outcome data will be calculated as mean difference or standardized mean difference and 95% CIs. Methodological quality of randomized controlled trials (RCTs) will be assessed using Cochrane risk of bias tool and that of case-controlled studies (CCSs) will be appraised using Newcastle-Ottawa Tool. Statistical analysis will be conducted using RevMan 5.3 software. DISCUSSION: This study will summarize up-to-date high-quality RCTs and CCSs to assess the efficacy and safety of gabapentin for PLP after amputation in pediatric oncology. The findings of this study will help to determine whether or not gabapentin is effective and safe for children with PLP after amputation. SYSTEMATIC REVIEW REGISTRATION: INPLASY202060090.
BACKGROUND: Phantom limb pain (PLP) is a prevalent problem for children after amputation because of the chemotherapy treatment. Gabapentin is a potential option to manage PLP after amputation in pediatric oncology. However, no systematic review specifically investigated this topic. Thus, this study aims to appraise the efficacy and safety of gabapentin for post-amputation PLP in pediatric oncology. METHODS: Electronic databases (Cochrane Library, MEDLINE, EMBASE, Web of Science, CINAHL, PsychINFO, Scopus, WANGFANG, and Chinese Biomedical Literature Database) will be systematically searched from the beginning to the present without limitations to publication status and language. Primary outcome is pain intensity. Secondary outcomes are analgesic drug consumption, sleep quality, depression, anxiety, health-related quality of life, and adverse events. The treatment effect of all dichotomous outcome data will be estimated as risk ratio and 95% confidence intervals (CIs) and that of continuous outcome data will be calculated as mean difference or standardized mean difference and 95% CIs. Methodological quality of randomized controlled trials (RCTs) will be assessed using Cochrane risk of bias tool and that of case-controlled studies (CCSs) will be appraised using Newcastle-Ottawa Tool. Statistical analysis will be conducted using RevMan 5.3 software. DISCUSSION: This study will summarize up-to-date high-quality RCTs and CCSs to assess the efficacy and safety of gabapentin for PLP after amputation in pediatric oncology. The findings of this study will help to determine whether or not gabapentin is effective and safe for children with PLP after amputation. SYSTEMATIC REVIEW REGISTRATION: INPLASY202060090.
Authors: Patti L Ephraim; Stephen T Wegener; Ellen J MacKenzie; Timothy R Dillingham; Liliana E Pezzin Journal: Arch Phys Med Rehabil Date: 2005-10 Impact factor: 3.966
Authors: Doralina L Anghelescu; Cassandra N Kelly; Brenda D Steen; Jianrong Wu; Huiyun Wu; Brian M DeFeo; Kristin Scobey; Laura Burgoyne Journal: Rehabil Oncol Date: 2016-07
Authors: D M Ehde; J M Czerniecki; D G Smith; K M Campbell; W T Edwards; M P Jensen; L R Robinson Journal: Arch Phys Med Rehabil Date: 2000-08 Impact factor: 3.966
Authors: Christopher L Wu; Shefali Agarwal; Prabhav K Tella; Brendan Klick; Michael R Clark; Jennifer A Haythornthwaite; Mitchell B Max; Srinivasa N Raja Journal: Anesthesiology Date: 2008-08 Impact factor: 7.892